• Explore /
  • Poster
  • / Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.

Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.

Abstract Video & Slides Poster

Authors

null

Hartmut Dohner

Ulm University Hospital, Ulm, Germany

Hartmut Dohner , Pau Montesinos , Susana Vives Polo , Ewa Zarzycka , Jianxiang Wang , Giambattista Bertani , Michael Heuser , Rodrigo T. Calado , Andre C. Schuh , Su-Peng Yeh , Adolfo de la Fuente Burguera , Claudio Cerchione , Scott Daigle , Jianan Hui , Shuchi Sumant Pandya , Diego A. Gianolio , Christian Recher , Stéphane De Botton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03173248

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7042)

DOI

10.1200/JCO.2022.40.16_suppl.7042

Abstract #

7042

Poster Bd #

273

Abstract Disclosures

Similar Posters

First Author: Stéphane De Botton

First Author: Stéphane De Botton

First Author: Chengyuan Gu

First Author: Gail J. Roboz